EC Number |
Inhibitors |
Structure |
---|
2.4.1.16 | (2R,3R,4R,5R)-2-[(1-ethylphosphonyl)-1,1-difluoromethyl]-3,4-dihydroxy-5-hydroxymethyl-pyrrolidine |
IC50: 1.6 mM |
|
2.4.1.16 | (2R,3R,4R,5S)-2-[(1-ethylphosphonyl)-1,1-difluoromethyl]-3,4-dihydroxy-5-hydroxymethyl-pyrrolidine |
IC50: 38 mM |
|
2.4.1.16 | (2S,3R,4R,5R)-2-[(1-ethylphosphonyl)-1,1-difluoromethyl]-3,4-dihydroxy-5-hydroxymethyl-pyrrolidine |
IC50: 4.0 mM |
|
2.4.1.16 | 1-(2,2-dibutyl-5-(3,5-dimethylphenyl)-1,3,4-oxadiazol-3(2H)-yl)ethanone |
0.25 mM, about 30% residual activity |
|
2.4.1.16 | 1-(2-(1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)acetyl)pyrrolidine-2-carboxylic acid |
75.5% inhibition at 0.3 mg/ml |
|
2.4.1.16 | 1-Geranyl-2-methylbenzimidazole |
weak |
|
2.4.1.16 | 1-[2,2-dibutyl-5-(2-chlorophenyl)-1,3,4-oxadiazol-3(2H)-yl]ethanone |
0.25 mM, about 10% residual activity |
|
2.4.1.16 | 1-[2,2-dibutyl-5-(4-chlorophenyl)-1,3,4-oxadiazol-3(2H)-yl]ethanone |
0.25 mM, about 30% residual activity |
|
2.4.1.16 | 1-[2,2-dibutyl-N-[(2,6-difluorophenyl)carbonyl]-5-(3,5-dimethylphenyl)-1,3,4-oxadiazol-3(2H)-yl]ethanone |
0.25 mM, about 20% residual activity |
|
2.4.1.16 | 1-[2,2-dibutyl-N-[(2-chlorophenyl)carbonyl]-5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-3(2H)-yl]ethanone |
0.25 mM, about 15% residual activity |
|